Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with
docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new
blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting
agents are intended to target the differences between these tumor blood vessels and the blood
vessels in normal tissues.